Answers are grounded in this paper and cite their sources.
Bovine norovirus (BNoV) can cause acute diarrhea in calves and is highly contagious. Currently, no clinically effective therapeutic drugs are available, and vaccination is one of the most effective measures for controlling this infectious disease. In this study, a recombinant multi-epitope vaccine was constructed using a molecular adjuvant fusion design. In vitro safety assays showed that the recombinant protein at various concentrations exhibited no significant cytotoxicity to cells, and in vivo assessments indicated that the vaccine caused no pathological damage to major organs and induced no hemolytic reactions in experimental animals. The immunogenicity evaluation showed that the vaccine specifically induced high-titer IgG antibodies, significantly increased Th1-type cytokine levels, promoted splenocyte proliferation, and activated specific cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL); moreover, it increased the proportion of CD4+ and CD8+ T cells. In conclusion, the recombinant protein vaccine developed in this study exhibited a satisfactory safety profile and elicited robust IgG and related cellular immune responses, providing important experimental evidence for the further development of a bovine norovirus vaccine.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: